Vor Biopharma is a biopharmaceutical company developing novel therapies for treating cancer. It develops a health and safety commission technology platform to address the limitations of the immunotherapies, including antibody-drug conjugates, bispecific antibodies, and chimeric antigen receptor T cells. The company engineers hematopoietic stem cells (eHSCs) to protect the blood and bone marrow from the toxic effects of antigen-targeted therapies, protecting healthy cells from depletion.